Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.

MLA

Viale, G., et al. “Immunohistochemical versus Molecular (BluePrint and MammaPrint) Subtyping of Breast Carcinoma. Outcome Results from the EORTC 10041/BIG 3-04 MINDACT Trial.” Breast Cancer Research & Treatment, vol. 167, no. 1, Jan. 2018, pp. 123–31. EBSCOhost, https://doi.org/10.1007/s10549-017-4509-9.

APA

Viale, G., de Snoo, F. A., Slaets, L., Bogaerts, J., van, t V. L., Rutgers, E. J., Piccart-Gebhart, M. J., Stork-Sloots, L., Glas, A., Russo, L., Dell, O. P., Tryfonidis, K., Litière, S., Cardoso, F., & for the MINDACT investigators. (2018). Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. Breast Cancer Research & Treatment, 167(1), 123–131. https://doi.org/10.1007/s10549-017-4509-9

Chicago

Viale, G., F. A. de Snoo, L. Slaets, J. Bogaerts, t Veer, L. van, E. J. Rutgers, M. J. Piccart-Gebhart, et al. 2018. “Immunohistochemical versus Molecular (BluePrint and MammaPrint) Subtyping of Breast Carcinoma. Outcome Results from the EORTC 10041/BIG 3-04 MINDACT Trial.” Breast Cancer Research & Treatment 167 (1): 123–31. doi:10.1007/s10549-017-4509-9.